Aprea Therapeutics Inc.

0.8800-0.0400-4.35%Vol 135.44K1Y Perf -74.08%
Aug 16th, 2022 16:00 DELAYED
BID0.8800 ASK0.8890
Open0.9100 Previous Close0.9200
Pre-Market- After-Market0.86
 - -  -0.02 -2.26%
Target Price
3.33 
Analyst Rating
Moderate Buy 2.33
Potential %
278.41 
Finscreener Ranking
 —    -
Insiders Trans % 3/6/12 mo.
100/33/-56 
Value Ranking
 —    -
Insiders Value % 3/6/12 mo.
100/-2/-86 
Growth Ranking
 —    -
Insiders Shares Cnt. % 3/6/12 mo.
100/42/-36 
Income Ranking
 —    -
Price Range Ratio 52W %
5.15 
Earnings Rating
Market Cap20.59M 
Earnings Date
11th Aug 2022
Alpha-0.06 Standard Deviation0.27
Beta0.40 

Today's Price Range

0.85000.00

52W Range

0.62005.67

Summary:

Sell

Technical Indicators: Neutral
Moving Averages: Strong Sell
Performance
1 Week
-11.65%
1 Month
-21.43%
3 Months
29.99%
6 Months
-50.56%
1 Year
-74.08%
3 Years
-
5 Years
-
10 Years
-

TickerPriceChg.Chg.%
APRE0.8800-0.0400-4.35
AAPL173.03-0.1600-0.09
GOOG122.51-0.3700-0.30
MSFT292.71-0.7600-0.26
XOM91.46-0.8600-0.93
WFC46.060.31000.68
JNJ167.571.48000.89
FB196.640.99000.51
GE81.071.26001.58
JPM123.631.17000.96
 
Earnings HistoryEstimateReportedSurprise %
Q02 2022-0.38-0.99-160.53
Q01 2022-0.38-0.365.26
Q04 2021-0.44-0.3618.18
Q03 2021-0.44-0.45-2.27
Q02 2021-0.47-0.48-2.13
Q01 2021-0.52-0.4611.54
Q04 2020-0.63-0.73-15.87
Q03 2020-0.77-0.5824.68
Earnings Per EndEstimateRevision %Trend
----
----
----
----
Next Report Date-
Estimated EPS Next Report-0.38
Estimates Count2
EPS Growth Next 5 Years %-
Volume Overview
Volume135.44K
Shares Outstanding23.40K
Shares Float19.93M
Trades Count429
Dollar Volume120.85K
Avg. Volume420.03K
Avg. Weekly Volume113.56K
Avg. Monthly Volume323.34K
Avg. Quarterly Volume823.19K

Aprea Therapeutics Inc. (NASDAQ: APRE) stock closed at 0.88 per share at the end of the most recent trading day (a -4.35% change compared to the prior day closing price) with a volume of 135.44K shares and market capitalization of 20.59M. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 13 people. Aprea Therapeutics Inc. CEO is Christian S. Schade.

The one-year performance of Aprea Therapeutics Inc. stock is -74.08%, while year-to-date (YTD) performance is -69.34%. APRE stock has a five-year performance of %. Its 52-week range is between 0.62 and 5.6699, which gives APRE stock a 52-week price range ratio of 5.15%

Aprea Therapeutics Inc. currently has a PE ratio of -0.60, a price-to-book (PB) ratio of 0.51, a price-to-sale (PS) ratio of -, a price to cashflow ratio of -, a PEG ratio of 2.32, a ROA of -54.15%, a ROC of -62.51% and a ROE of -62.79%. The company’s profit margin is -%, its EBITDA margin is -%, and its revenue ttm is $0.00 , which makes it $0.00 revenue per share.

Of the last four earnings reports from Aprea Therapeutics Inc., there were 2 positive earnings surprise and 2 negative earnings surprise. The company has EPS estimate of $-0.38 for the next earnings report. Aprea Therapeutics Inc.’s next earnings report date is -.

The consensus rating of Wall Street analysts for Aprea Therapeutics Inc. is Moderate Buy (2.33), with a target price of $3.33, which is +278.41% compared to the current price. The earnings rating for Aprea Therapeutics Inc. stock is (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).

Aprea Therapeutics Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.

Aprea Therapeutics Inc. has a Sell technical analysis rating based on Technical Indicators (ADX : 20.53, ATR14 : 0.09, CCI20 : -82.41, Chaikin Money Flow : 0.20, MACD : -0.01, Money Flow Index : 47.71, ROC : -15.60, RSI : 45.08, STOCH (14,3) : 4.00, STOCH RSI : 0.00, UO : 36.91, Williams %R : -96.00), Simple Moving Averages and Exponential Moving Averages.

Aggregated Insider Trades of Aprea Therapeutics Inc. in the last 12-months were: Bernd R. Seizinger (Buy at a value of $35 500), Christian Stanton Schade (Buy at a value of $24 124), Eyal C. , Attar (Sold 103 936 shares of value $274 020 ), Gregory A. Korbel (Option Excercise at a value of $151 800), Gregory A. Korbel (Sold 181 380 shares of value $895 022 ), Lars Abrahmsen (Option Excercise at a value of $69 000), Lars Abrahmsen (Sold 75 000 shares of value $368 750 )

Analyst RatingsCurrent1 M ago3 M ago
Strong Buy
1 (33.33 %)
1 (33.33 %)
0 (0.00 %)
Moderate Buy
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Hold
2 (66.67 %)
2 (66.67 %)
2 (100.00 %)
Moderate Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Strong Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Summary RatingModerate Buy
2.33
Moderate Buy
2.33
Hold
3.00

Aprea Therapeutics Inc.

Aprea Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing cancer therapeutics that reactivate mutant p53 tumor suppressor protein. Its product candidate, APR-246, is a small molecule p53 reactivator that is in late-stage clinical development for hematologic malignancies, including myelodysplastic syndromes (MDS), and acute myeloid leukemia (AML).

CEO: Christian S. Schade

Telephone: +1 617 463-9385

Address: 535 Boylston Street, Boston 02116, MA, US

Number of employees: 13

Bearish or Bullish?
WeekMonthThree MonthsSix Months

Bearish Bullish

50%50%

Bearish Bullish

60%40%

Bearish Bullish

63%38%

Bearish Bullish

58%42%


News

Stocktwits